| Literature DB >> 35085358 |
Sung Ha Lim1, Solam Lee1,2, Young Bin Lee1, Chung Hyeok Lee1, Jong Won Lee1, Sang-Hoon Lee1, Ju Yeong Lee1, Joung Soo Kim3, Mi Youn Park4, Sang Baek Koh2, Eung Ho Choi1.
Abstract
Whether having a tattoo increases the risk of transfusion-transmitted diseases (TTDs) is controversial. Although a few studies have suggested a strong association between having tattoos and TTDs, other studies have not shown the significance of the association. In addition, previous studies mainly focused only on hepatitis C viral infections. The objective of our study was to identify the prevalence and risk of TTDs in people with tattoos as compared with the non-tattooed population. A systematic review of the studies published before January 22, 2021, was performed using the Pubmed, Embase, and Web of Science databases. Observational studies on hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), and syphilis infections in people with and without tattoos were included. Studies that reported disease status without serological confirmation were excluded. A total of 121 studies were quantitatively analyzed. HCV (odds ratio [OR], 2.37; 95% confidence interval [CI], 2.04-2.76), HBV (OR, 1.55; 95% CI, 1.31-1.83), and HIV infections (OR, 3.55; 95% CI, 2.34-5.39) were more prevalent in the tattooed population. In subgroup analyses, the prevalence of HCV infection was significantly elevated in the general population, hospital patient, blood donor, intravenous (IV) drug user, and prisoner groups. IV drug users and prisoners showed high prevalence rates of HBV infection. The prevalence of HIV infection was significantly increased in the general population and prisoner groups. Having a tattoo is associated with an increased prevalence of TTDs. Our approach clarifies in-depth and supports a guideline for TTD screening in the tattooed population.Entities:
Mesh:
Year: 2022 PMID: 35085358 PMCID: PMC8794209 DOI: 10.1371/journal.pone.0262990
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1PRISMA flowchart for study selection.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram of literature search and study selection.
Summary of the included studies.
| Variables | N | % | Variables | N | % | |
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| Iran | 23 | 19.0 | General population | 36 | 31.0 | |
| Brazil | 13 | 10.7 | Hospital patients | 24 | 20.7 | |
| U.S.A. | 12 | 9.9 | Blood donors | 6 | 5.2 | |
| India | 9 | 7.4 | Intravenous drug users | 25 | 21.6 | |
| Australia | 6 | 5.0 | Prisoners | 25 | 21.6 | |
| Mexico | 5 | 4.1 |
| |||
| Taiwan | 5 | 4.1 | HCV | 86 | ||
| Thailand | 5 | 4.1 | Anti-HCV | 81 | 94.2 | |
| Nigeria | 4 | 3.3 | HCV-RNA | 5 | 5.8 | |
| Pakistan | 3 | 2.5 | HBV | 48 | ||
| Bosnia | 2 | 1.7 | HBsAg | 38 | 79.2 | |
| Canada | 2 | 1.7 | Anti-HBc | 6 | 12.5 | |
| Ethiopia | 2 | 1.7 | HBV-DNA | 3 | 6.3 | |
| France | 2 | 1.7 | HBs Ab | 1 | 2.1 | |
| Italy | 2 | 1.7 | HIV | 20 | ||
| Spain | 2 | 1.7 | Anti-HIV | 20 | 100 | |
| Others | 24 | 19.8 | Syphilis | 3 | ||
| RPR, VDRL test | 3 | 100 | ||||
Abbreviations: HCV, hepatitis C virus; HBV, hepatitis B virus; HIV, human immunodeficiency virus; RPR, rapid plasma regain; VDRL, venereal disease research laboratory.
Fig 2Forest plots summarizing the meta-analysis.
Forest plots of the meta-analysis. (A) HCV, (B) HBV, (C) HIV, and (D) Syphilis. Abbreviations: HCV, hepatitis C virus; HBV, hepatitis B virus; HIV, human immunodeficiency virus.
Fig 3Funnel plots for the assessment of publication bias.
Funnel plots of the meta-analyses. (A) HCV, (B) HBV, and (C) HIV. Abbreviations: HCV, hepatitis C virus; HBV, hepatitis B virus; HIV, human immunodeficiency virus.
Meta-analyzed estimates of the prevalence rates of transfusion-transmitted diseases among subjects with tattoos.
| Disease | Subgroup | No. of studies | No. of tattoo users | No. of controls | OR (95% CI) |
| Egger’s test |
|---|---|---|---|---|---|---|---|
|
| (All) | 86 | 30665 | 171103 | 2.89 (2.48–3.37) | 85% | 0.01 |
| General population | 18 | 5812 | 31492 | 2.94 (2.32–3.73) | 70% | 0.43 | |
| Hospital patients | 16 | 4919 | 46114 | 4.27 (3.21–5.68) | 53% | 0.71 | |
| Blood donors | 5 | 812 | 67477 | 3.27 (1.48–7.21) | 77% | 0.85 | |
| Intravenous drug users | 22 | 3733 | 3501 | 2.37 (1.54–3.67) | 92% | 0.08 | |
| Prisoners | 19 | 12890 | 13275 | 2.99 (2.50–3.56) | 66% | 0.12 | |
|
| (All) | 48 | 25886 | 91495 | 1.55 (1.31–1.83) | 84% | 0.19 |
| General population | 16 | 5185 | 43828 | 2.04 (1.42–2.93) | 85% | 0.04 | |
| Hospital patients | 12 | 2475 | 27141 | 1.97 (1.15–3.37) | 91% | 0.04 | |
| b0.91 (0.54–1.53) | |||||||
| Intravenous drug users | 6 | 1276 | 1166 | 1.40 (1.13–1.74) | 0% | 0.02 | |
| Prisoners | 9 | 14336 | 13923 | 1.35 (1.07–1.70) | 74% | 0.15 | |
|
| (All) | 20 | 6917 | 17873 | 3.55 (2.34–5.39) | 85% | 0.10 |
| General population | 5 | 1010 | 6976 | 2.73 (1.35–5.54) | 64% | 0.71 | |
| Hospital patients | 3 | 874 | 2548 | 5.71 (0.87–37.47) | 86% | 0.20 | |
| Intravenous drug users | 3 | 490 | 581 | 4.33 (0.21–88.3) | 95% | 0.67 | |
| Prisoners | 5 | 3712 | 4069 | 4.29 (3.32–5.54) | 0% | 0.21 | |
|
| (All) | 3 | 692 | 2203 | 1.55 (0.76–3.17) | 0% | - |
Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; HCV, hepatitis C virus; HBV, hepatitis B virus; HIV, human immunodeficiency virus
aSubgroup analyses were performed when three or more studies were available for each subgroup.
bAdjusted OR with the trim-and-fill method for possible publication bias.